UBS Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
UBS initiates coverage on Biohaven Pharmaceutical Holding (NYSE: BHVN) with a Buy rating and a price target of $108.00.
Shares of Biohaven Pharmaceutical Holding closed at $80.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Catena AB (CATE:SS) at Equalweight
- Barclays Starts VIB Vermoegen AG (VIH1:GR) at Overweight
- UBS Starts AC Energy Corp (ACEN:PM) at Neutral
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!